Study #2015-0864
Phase II study of single-agent crenolanib in recurrent/refractory glioblastoma with PDGFRA gene amplification
MD Anderson Study Status
Not Accepting
Treatment Agent
crenolanib
Description
This is a proof of concept, single-arm study to investigate crenolanib monotherapy in patients with recurrent/refractory glioblastoma with PDGFRA gene amplification by assessing the progression-free survival (PFS) at 6 months. Crenolanib will be given orally starting at 100 mg TID continuously until disease progression, unacceptable toxicity, or consent withdrawal.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Recurrent/Refractory Glioblastoma
Study phase:
Phase II
Physician name:
Barbara O'Brien
Department:
Neuro-Oncology
For general questions about clinical trials:
1-866-915-0406
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.